File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: Pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis

TitleIncidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: Pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis
Authors
KeywordsCyclo-oxygenase inhibitors
Gastrointestinal
NSAIDs
Ulcers
Issue Date2010
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwell-synergy.com/loi/ijrd
Citation
International Journal Of Rheumatic Diseases, 2010, v. 13 n. 2, p. 151-157 How to Cite?
AbstractAim: To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors. Methods: Patients with a clinical diagnosis of OA or RA of at least 3 months were randomized to 12 weeks of double-blind treatment with celecoxib 100 mg twice daily (n = 440) or diclofenac 50 mg twice daily (n = 440). The primary outcome was the gastric and/or duodenal ulcer rate at endpoint as determined by upper gastrointestinal endoscopy performed during the screening week, and at endpoint. Results: There was no significant difference in the overall incidence of gastroduodenal ulcers at 12-week endpoint for celecoxib compared to diclofenac (2.8% vs. 5.1%; Cochran-Mantel-Haenszel [CMH] χ2 P = 0.083). However, there was a significantly lower incidence of gastric ulcers on celecoxib versus diclofenac (0.5% vs. 3.6%; CMH χ2 P = 0.002). Approximately 59% of patients in both treatment groups had no visible gastric lesions at endpoint; and a similar proportion were found to have one or more erosions on celecoxib (n = 85; 21.4%) and diclofenac (N = 91; 23.3%). A survival analysis of time to ulcer was significant for gastric ulcers (log-rank P = 0.004), but not for duodenal ulcers, or for gastroduodenal ulcers combined. Fewer patients reported at least one adverse event on celecoxib compared to diclofenac (42.4% vs. 50.3%; χ2, 5.52; P = 0.019). Conclusions: In Asian patients with minimal significant risk factors, treatment with celecoxib was associated with a modest but significantly reduced incidence of gastric ulcers at the end of 12 weeks. © 2010 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/139482
ISSN
2015 Impact Factor: 1.914
2015 SCImago Journal Rankings: 0.536
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheung, Ren_HK
dc.contributor.authorCheng, TTen_HK
dc.contributor.authorDong, Yen_HK
dc.contributor.authorLin, HYen_HK
dc.contributor.authorLai, Ken_HK
dc.contributor.authorLau, CSen_HK
dc.contributor.authorFeng, Hen_HK
dc.contributor.authorParsons, Ben_HK
dc.date.accessioned2011-09-23T05:50:33Z-
dc.date.available2011-09-23T05:50:33Z-
dc.date.issued2010en_HK
dc.identifier.citationInternational Journal Of Rheumatic Diseases, 2010, v. 13 n. 2, p. 151-157en_HK
dc.identifier.issn1756-1841en_HK
dc.identifier.urihttp://hdl.handle.net/10722/139482-
dc.description.abstractAim: To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors. Methods: Patients with a clinical diagnosis of OA or RA of at least 3 months were randomized to 12 weeks of double-blind treatment with celecoxib 100 mg twice daily (n = 440) or diclofenac 50 mg twice daily (n = 440). The primary outcome was the gastric and/or duodenal ulcer rate at endpoint as determined by upper gastrointestinal endoscopy performed during the screening week, and at endpoint. Results: There was no significant difference in the overall incidence of gastroduodenal ulcers at 12-week endpoint for celecoxib compared to diclofenac (2.8% vs. 5.1%; Cochran-Mantel-Haenszel [CMH] χ2 P = 0.083). However, there was a significantly lower incidence of gastric ulcers on celecoxib versus diclofenac (0.5% vs. 3.6%; CMH χ2 P = 0.002). Approximately 59% of patients in both treatment groups had no visible gastric lesions at endpoint; and a similar proportion were found to have one or more erosions on celecoxib (n = 85; 21.4%) and diclofenac (N = 91; 23.3%). A survival analysis of time to ulcer was significant for gastric ulcers (log-rank P = 0.004), but not for duodenal ulcers, or for gastroduodenal ulcers combined. Fewer patients reported at least one adverse event on celecoxib compared to diclofenac (42.4% vs. 50.3%; χ2, 5.52; P = 0.019). Conclusions: In Asian patients with minimal significant risk factors, treatment with celecoxib was associated with a modest but significantly reduced incidence of gastric ulcers at the end of 12 weeks. © 2010 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd.en_HK
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwell-synergy.com/loi/ijrden_HK
dc.relation.ispartofInternational Journal of Rheumatic Diseasesen_HK
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.subjectCyclo-oxygenase inhibitorsen_HK
dc.subjectGastrointestinalen_HK
dc.subjectNSAIDsen_HK
dc.subjectUlcersen_HK
dc.subject.meshArthritis, Rheumatoid - drug therapy - epidemiology-
dc.subject.meshCyclooxygenase 2 Inhibitors - adverse effects-
dc.subject.meshDiclofenac - adverse effects-
dc.subject.meshOsteoarthritis - drug therapy - epidemiology-
dc.subject.meshPeptic Ulcer - chemically induced - diagnosis - epidemiology-
dc.titleIncidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: Pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritisen_HK
dc.typeArticleen_HK
dc.identifier.emailLau, CS:cslau@hku.hken_HK
dc.identifier.authorityLau, CS=rp01348en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1756-185X.2010.01463.xen_HK
dc.identifier.pmid20536600-
dc.identifier.scopuseid_2-s2.0-77953800162en_HK
dc.identifier.hkuros195384en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77953800162&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume13en_HK
dc.identifier.issue2en_HK
dc.identifier.spage151en_HK
dc.identifier.epage157en_HK
dc.identifier.isiWOS:000277320400008-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridCheung, R=7202397517en_HK
dc.identifier.scopusauthoridCheng, TT=8592085100en_HK
dc.identifier.scopusauthoridDong, Y=7403390603en_HK
dc.identifier.scopusauthoridLin, HY=7405572432en_HK
dc.identifier.scopusauthoridLai, K=7402135595en_HK
dc.identifier.scopusauthoridLau, CS=14035682100en_HK
dc.identifier.scopusauthoridFeng, H=36608011300en_HK
dc.identifier.scopusauthoridParsons, B=35828789400en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats